TVARDI THERAPEUTICS INC (TVRD:NASDAQ)
$2.1 0 (0%)
Analysed TVARDI THERAPEUTICS INC (TVRD:NASDAQ) News Sources
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
31-03-2026
yahoo.com
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
02-04-2026
yahoo.com
Sector Update: Health Care Stocks Fall Late Afternoon
20-04-2026
yahoo.com
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
08-05-2026
yahoo.com
Tvardi Therapeutics to Participate in Upcoming Investor Events
21-05-2026
yahoo.com
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
07-07-2026
yahoo.com
Top Midday Gainers
08-07-2026
yahoo.com
Sector Update: Healthcare Stocks Lower Wednesday Afternoon
08-07-2026
yahoo.com
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
09-07-2026
yahoo.com
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
30-07-2026
yahoo.com
What is the current price of TVARDI THERAPEUTICS INC (TVRD:NASDAQ)?
The current price of TVARDI THERAPEUTICS INC (TVRD:NASDAQ) is $2.1.
TVARDI THERAPEUTICS INC (TVRD:NASDAQ) absolute price change since previous trading day?
The absolute price change of TVARDI THERAPEUTICS INC (TVRD:NASDAQ) since the previous trading day is $0.
TVARDI THERAPEUTICS INC (TVRD:NASDAQ) percentage price change since previous trading day?
The percentage price change of TVARDI THERAPEUTICS INC (TVRD:NASDAQ) since the previous trading day is 0%.
What is the most recent average sentiment score for TVARDI THERAPEUTICS INC (TVRD:NASDAQ)?
The most recent average sentiment score for TVARDI THERAPEUTICS INC (TVRD:NASDAQ) is 75 out of 100.
What is the most recent average sentiment for TVARDI THERAPEUTICS INC (TVRD:NASDAQ)?
The most recent sentiment for TVARDI THERAPEUTICS INC (TVRD:NASDAQ) is .
SEC-8K** Filing Available For TVARDI THERAPEUTICS INC (TVRD:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.